Neumora Therapeutics Inc Financials
This page shows Neumora Therapeutics Inc (NMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash runway, not reported earnings, is the governing mechanic as R&D-heavy spending consumes a mostly cash asset base.
FY2025 looked leaner on the expense lines, with R&D down to$176M from$201M . Yet operating cash outflow still worsened to-$206M from-$183M , so program funding needs are still overwhelming the savings visible in reported expenses and cash conversion has not improved.
With
Cash fell to
Financial Health Signals
Neumora Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Neumora Therapeutics Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Neumora Therapeutics Inc used $0.87 of operating cash (-$206.4M OCF vs $236.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Neumora Therapeutics Inc reported an operating loss of $241.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Neumora Therapeutics Inc's EBITDA was -$240.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.3% from the prior year.
Neumora Therapeutics Inc reported $236.9M in net income in fiscal year 2025. This represents a decrease of 2.8% from the prior year.
Neumora Therapeutics Inc earned -$1.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 5.2% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Neumora Therapeutics Inc held $182.5M in cash against $54.5M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Neumora Therapeutics Inc's ROE was 228.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 143.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Neumora Therapeutics Inc invested $176.1M in research and development in fiscal year 2025. This represents a decrease of 12.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NMRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $176.1M-12.4% | $200.9M+40.8% | $142.7M+55.6% | $91.7M |
| SG&A Expenses | N/A | $60.1M-3.9% | $62.5M+37.5% | $45.5M+46.1% | $31.1M |
| Operating Income | N/A | -$241.2M+8.5% | -$263.5M-4.5% | -$252.1M-85.5% | -$135.9M |
| Interest Expense | N/A | $2.0M | $0 | N/A | N/A |
| Income Tax | N/A | $130K-27.0% | $178K-33.6% | $268K | N/A |
| Net Income | N/A | $236.9M-2.8% | $243.8M+203.3% | -$235.9M-80.2% | -$130.9M |
| EPS (Diluted) | — | -$1.45+5.2% | -$1.53+57.9% | -$3.63 | -$4.81 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NMRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $191.0M-39.7% | $317.0M-36.1% | $496.2M+16.4% | $426.2M |
| Current Assets | $190.5M-39.3% | $314.1M-34.3% | $478.3M+23.3% | $388.0M |
| Cash & Equivalents | $182.5M+28.4% | $142.1M-62.0% | $374.0M+55.2% | $240.9M |
| Total Liabilities | $87.2M+191.5% | $29.9M+10.3% | $27.1M-96.9% | $873.1M |
| Current Liabilities | $32.5M+8.6% | $29.9M+19.0% | $25.1M+6.0% | $23.7M |
| Long-Term Debt | $54.5M | $0 | N/A | N/A |
| Total Equity | $103.9M-63.8% | $287.1M-38.8% | $469.1M+205.0% | -$446.9M |
| Retained Earnings | -$1.2B-25.0% | -$947.2M-34.7% | -$703.4M-50.5% | -$467.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
NMRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$180.5M | -$206.4M-12.8% | -$182.9M-12.0% | -$163.3M-42.1% | -$114.9M |
| Capital Expenditures | N/A | N/A | N/A | $117K-77.1% | $511K |
| Free Cash Flow | N/A | N/A | N/A | -$163.4M-41.6% | -$115.4M |
| Investing Cash Flow | $94.0M | $168.5M+338.8% | -$70.6M-209.6% | $64.4M+138.3% | -$168.0M |
| Financing Cash Flow | $78.8M | $77.1M+256.8% | $21.6M-90.7% | $231.9M+100.4% | $115.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NMRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Return on Equity | 228.1%+143.2pp | 84.9%+135.2pp | -50.3% | N/A |
| Return on Assets | 124.0%+47.1pp | 76.9%+124.5pp | -47.5%-16.8pp | -30.7% |
| Current Ratio | 5.87-4.6x | 10.51-8.5x | 19.05+2.7x | 16.37 |
| Debt-to-Equity | 0.53+0.5x | 0.00-0.1x | 0.06 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Neumora Therapeutics Inc Ranks
Frequently Asked Questions
Is Neumora Therapeutics Inc profitable?
Yes, Neumora Therapeutics Inc (NMRA) reported a net income of $236.9M in fiscal year 2025.
What is Neumora Therapeutics Inc's EBITDA?
Neumora Therapeutics Inc (NMRA) had EBITDA of -$240.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Neumora Therapeutics Inc have?
As of fiscal year 2025, Neumora Therapeutics Inc (NMRA) had $182.5M in cash and equivalents against $54.5M in long-term debt.
What is Neumora Therapeutics Inc's return on equity (ROE)?
Neumora Therapeutics Inc (NMRA) has a return on equity of 228.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Neumora Therapeutics Inc's operating cash flow?
Neumora Therapeutics Inc (NMRA) recorded an outflow of $206.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Neumora Therapeutics Inc's total assets?
Neumora Therapeutics Inc (NMRA) had $191.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Neumora Therapeutics Inc spend on research and development?
Neumora Therapeutics Inc (NMRA) invested $176.1M in research and development during fiscal year 2025.
What is Neumora Therapeutics Inc's current ratio?
Neumora Therapeutics Inc (NMRA) had a current ratio of 5.87 as of fiscal year 2025, which is generally considered healthy.
What is Neumora Therapeutics Inc's debt-to-equity ratio?
Neumora Therapeutics Inc (NMRA) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neumora Therapeutics Inc's return on assets (ROA)?
Neumora Therapeutics Inc (NMRA) had a return on assets of 124.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Neumora Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Neumora Therapeutics Inc (NMRA) had $182.5M in cash against an annual operating cash burn of $206.4M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Neumora Therapeutics Inc's Piotroski F-Score?
Neumora Therapeutics Inc (NMRA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neumora Therapeutics Inc's earnings high quality?
For every $1 of reported earnings, Neumora Therapeutics Inc (NMRA) used $0.87 of operating cash (-$206.4M OCF vs $236.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Neumora Therapeutics Inc cover its interest payments?
Neumora Therapeutics Inc (NMRA) reported an operating loss of $241.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.